

South Korea



South Korea

Understanding the applicable framework

KRPIA describes ethical-business and fair-competition arrangements, but retrieved public documents include historical versions (Korea Research-based Pharma Industry Association [KRPIA], n.d.).

What companies need to understand

Check identity, governance and signing authority and distinguish individual experience, organisational advice and collective findings. Explain documentation and allow realistic time for consultation, particularly where volunteers manage administration.

What patient organisations need to understand

The company should identify sources for funding, services, event and communication requirements. A familiar hospitality figure is not automatically a patient limit. Record the basis of material decisions.

Distinguish support and services, explain review and disclosure and provide a route to question independence concerns.

Personal information

PIPA Article 23 restricts sensitive health-information processing and provides specified grounds including separate consent or legislative permission (Personal Information Protection Act, 2011, as amended).

Separate participation, health collection, recording and publication. Assess third-party and overseas access before choosing systems, and consider identifiability in small communities.

Regulatory and access participation

HIRA assesses clinical and economic evidence; newly listed medicine pricing involves NHIS negotiation (Health Insurance Review and Assessment Service [HIRA], n.d.).

Practical example and local checks

For treatment-burden advice, define the contribution and whether research is involved. Confirm contracts, payments and review, then privacy, safety and publication. Keep later official access input independent and check its procedure.